Equity research analysts predict that Elanco Animal Health Incorporated (NYSE: ELAN) will post revenue of $ 1.10 billion for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Elanco Animal Health’s earnings, with estimates ranging from $ 1.09 billion to $ 1.12 billion. Elanco Animal Health reported sales of $ 1.14 billion in the same quarter last year, indicating a negative growth rate of 3.5% year-over-year. The company is expected to release its next results on Wednesday February 23.
According to Zacks, analysts expect Elanco Animal Health to report annual revenue of $ 4.75 billion for the current fiscal year, with estimates ranging from $ 4.75 billion to $ 4.77 billion. dollars. For the next fiscal year, analysts predict the company will post sales of $ 4.86 billion, with estimates ranging from $ 4.79 billion to $ 4.93 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research companies that track Elanco Animal Health.
Elanco Animal Health (NYSE: ELAN) last released its results on Friday, November 5. The company reported earnings per share of $ 0.19 for the quarter, beating Thomson Reuters’ consensus estimate of $ 0.17 per $ 0.02. Elanco Animal Health recorded a positive return on equity of 5.79% and a negative net margin of 14.56%. The company posted revenue of $ 1.13 billion in the quarter, compared to analysts’ estimates of $ 1.08 billion. During the same period of the previous year, the company achieved EPS of $ 0.13. The company’s revenue for the quarter increased 27.1% year-over-year.
Several equity research analysts have weighed on the company recently. Barclays reaffirmed a “conservation” note on Elanco Animal Health’s actions in a report released Wednesday. Stifel Nicolaus downgraded Elanco Animal Health from a ‘buy’ rating to a ‘keep’ rating and cut its target price for the share from $ 37.00 to $ 34.00 in a report released on Thursday 28 October. Zacks Investment Research upgraded Elanco Animal Health from a “sell” rating to a “keep” rating in a report released on Tuesday, November 9. Finally, Morgan Stanley assumed cover of Elanco Animal Health in a report released on Thursday, November 18. They set an “overweight” rating and a price target of $ 40.00 for the company. Five analysts rated the stock with a conservation rating and six gave the company’s stock a buy rating. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $ 37.25.
ELAN opened for $ 28.49 on Friday. The company has a 50-day moving average price of $ 31.91 and a 200-day moving average price of $ 33.27. Elanco Animal Health has a twelve month low of $ 27.33 and a twelve month high of $ 37.49. The company has a debt to equity ratio of 0.82, a quick ratio of 1.30 and a current ratio of 2.32. The company has a market cap of $ 13.48 billion, a P / E ratio of -20.06, a price / earnings-growth ratio of 0.61, and a beta of 0.84.
In other news, Director R David Hoover bought 10,000 shares of the company in a trade that took place on Tuesday, November 30. The stock was acquired at an average cost of $ 29.38 per share, for a total transaction of $ 293,800.00. The purchase was disclosed in a file with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.11% of the company’s shares.
A number of large investors have recently changed their positions in ELAN. The Toronto Dominion Bank increased its holdings of Elanco Animal Health shares by 118.7% in the second quarter. The Toronto Dominion Bank now owns 1,385,303 shares of the company valued at $ 48,056,000 after purchasing an additional 751,804 shares during the last quarter. Man Group plc increased its stake in Elanco Animal Health shares by 371.7% in the second quarter. Man Group plc now owns 293,716 shares of the company valued at $ 10,188,000 after purchasing an additional 231,454 shares in the last quarter. Franklin Resources Inc. increased its holdings of Elanco Animal Health shares by 42.6% in the second quarter. Franklin Resources Inc. now owns 7,085,442 shares of the company valued at $ 245,794,000 after purchasing an additional 2,115,002 shares during the last quarter. Marshall Wace LLP increased its stake in Elanco Animal Health shares by 400.1% during the second quarter. Marshall Wace LLP now owns 522,823 shares of the company valued at $ 18,137,000 after purchasing an additional 418,272 shares during the last quarter. Finally, the Bank of Nova Scotia purchased a new equity interest in Elanco Animal Health during the second quarter for a value of $ 9,713,000. Hedge funds and other institutional investors hold 98.46% of the company’s shares.
About Elanco Animal Health
Elanco Animal Health, Inc is committed to the innovation, development, manufacture and marketing of products for companion animals and food animals. It offers products in the following four categories: Prevention of Disease in Companion Animals, Therapeutics in Companion Animals, Protein and Future Health of Food Animals and Ruminants and Pigs for Food.
Read more: Is the QQQ ETF Safe?
Get a Free Copy of Zacks’ Research Report on Elanco Animal Health (ELAN)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Elanco Animal Health now?
Before you consider Elanco Animal Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and Elanco Animal Health was not on the list.
While Elanco Animal Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here